PART I Overview We are a patient-focused, innovative, commercial-stage, global biopharmaceutical company with a substantial presence in both Greater China and the United States. We are focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. We intend to leverage our competencies and resources to positively impact human health. To that end, our experien...
Q2 FY2026 — expected 2026-08-06
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-26 | 2025-12-31 | 0001704292-26-000015 | EDGAR | 87K words |
| 2025-02-27 | 2024-12-31 | 0001628280-25-008409 | EDGAR | — |
| 2024-02-27 | 2023-12-31 | 0001628280-24-007235 | EDGAR | — |
| 2023-03-01 | 2022-12-31 | 0001628280-23-005832 | EDGAR | — |
| 2022-03-01 | 2021-12-31 | 0001193125-22-061312 | EDGAR | — |
| 2021-03-01 | 2020-12-31 | 0001193125-21-062279 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-06 | 2025-09-30 | 0001704292-25-000024 | EDGAR | 18K words |
| 2025-08-07 | 2025-06-30 | 0001628280-25-038548 | EDGAR | — |
| 2025-05-08 | 2025-03-31 | 0001628280-25-023411 | EDGAR | — |
| 2024-11-12 | 2024-09-30 | 0001628280-24-046824 | EDGAR | — |
| 2024-08-06 | 2024-06-30 | 0001628280-24-035231 | EDGAR | — |
| 2024-05-08 | 2024-03-31 | 0001628280-24-021689 | EDGAR | — |
| 2023-11-07 | 2023-09-30 | 0001628280-23-037358 | EDGAR | — |
| 2023-08-07 | 2023-06-30 | 0001628280-23-027773 | EDGAR | — |
| 2023-05-09 | 2023-03-31 | 0001628280-23-016816 | EDGAR | — |
| 2022-11-09 | 2022-09-30 | 0001628280-22-029246 | EDGAR | — |
| 2022-08-09 | 2022-06-30 | 0001628280-22-021975 | EDGAR | — |
| 2022-05-10 | 2022-03-31 | 0001193125-22-146354 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-02-26 | 0001704292-26-000014 | EDGAR | 5K words |
| 2025-11-06 | 0001704292-25-000023 | EDGAR | — |
| 2025-10-16 | 0001704292-25-000014 | EDGAR | — |
| 2025-08-07 | 0001628280-25-038547 | EDGAR | — |
| 2025-06-18 | 0001628280-25-032099 | EDGAR | — |
| 2025-05-08 | 0001628280-25-023410 | EDGAR | — |
| 2025-02-27 | 0001628280-25-008406 | EDGAR | — |
| 2025-01-03 | 0001628280-25-000261 | EDGAR | — |
| 2024-11-15 | 0001193125-24-259957 | EDGAR | — |
| 2024-11-13 | 0001628280-24-047588 | EDGAR | — |
163 total filings indexed. 135 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001704292 |
| Ticker | ZLAB |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | E9 |
| Website | https://www.zailaboratory.com |
| Listed | 2017-09-20 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report